Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
Go back to Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 63.65 +1.62 (2.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.03 | 52 Week High | $19.98 | |||
| Open | $61.52 | 52 Week Low | $10.52 | |||
| Day High | $64.34 | P/E | N/A | |||
| Day Low | $61.29 | EPS | $-1.45 | |||
| Volume | 6,152,225 | |||||
